Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (NASDAQ: CERT) delivers biosimulation solutions and model-informed drug development services that accelerate pharmaceutical innovation. This page provides comprehensive coverage of Certara's latest news, including regulatory milestones, strategic partnerships, and advancements in simulation technology.
Investors and industry professionals will find timely updates on earnings reports, product launches, and scientific developments shaping the drug development landscape. Our curated collection features press releases on regulatory submissions, technology platform enhancements, and collaborations with biopharma leaders.
Key focus areas include Certara's biosimulation software updates, regulatory science achievements, and innovations in quantitative pharmacology. Bookmark this page to stay informed about developments impacting clinical trial optimization and global drug approval processes.
Certara, Inc. reported its first quarter 2024 financial results, with revenue reaching $96.7 million, a 7% increase from the previous year. Software revenue grew by 19% to $39.3 million, while services revenue remained flat. The net loss was $4.7 million, with adjusted EBITDA at $29.1 million. The company reiterated its full-year 2024 financial guidance, expecting revenue between $385 million to $400 million.
FAQ
What is the current stock price of Certara (CERT)?
What is the market cap of Certara (CERT)?
